Triple-Negative Breast Cancer | Topics

 
Adding Carboplatin to Neoadjuvant Paclitaxel Improved Outcomes in TNBC
September 18, 2021

Although the addition of carboplatin to neoadjuvant paclitaxel followed by cyclophosphamide helped to improve outcomes for those with treatment-naïve triple-negative breast cancer, the addition of veliparib did not have an impact on pathologic complete response or event-free survival.

Atezolizumab TNBC Indication Withdrawn By Manufacturer After Talks With FDA
August 27, 2021

Atezolizumab will no longer be available for the treatment of patients with PD-L1–positive triple-negative breast cancer following withdrawal of the indication by the agent’s developer.

Leronlimab Provides a Significant Survival Benefit in Metastatic Triple-Negative Breast Cancer
August 25, 2021

Leronlimab yielded a notable increase in overall survival and progression-free survival in patients with metastatic triple-negative breast cancer.

Eganelisib Combination Therapies Demonstrate Promising Survival Benefit in Advanced Urothelial Carcinoma and TNBC
July 28, 2021

Novel eganelisib shows survival-extending potential in patients with triple-negative breast and bladder cancers.

FDA Approves Neoadjuvant Pembrolizumab Combination for Early TNBC Indication
July 27, 2021

Based on results of the KEYNOTE-522 trial, the FDA approved pembrolizumab, the first immunotherapy for this indication, plus chemotherapy as neoadjuvant treatment for patients with early-stage triple-negative breast cancer.

Leronlimab Plus Carboplatin Appears to Yield Survival Benefit in Metastatic Triple-Negative Breast Cancer
July 19, 2021

Patients with metastatic triple-negative breast cancer being treated with leronlimab and carboplatin have experienced a decrease in cancer-associated macrophage-like cells and an increase in survival benefit.

Event-Free Survival Improvement Noted in KEYNOTE-522 Study for Patients With Triple-Negative Breast Cancer
July 17, 2021

Pembrolizumab plus chemotherapy as adjuvant/neoadjuvant therapy demonstrated positive even-free survival outcomes in the KEYNOTE-522 study for patients with triple-negative breast cancer.

Sacituzumab Govitecan for Metastatic TNBC Retains Survival Advantage Over Chemotherapy
June 08, 2021

Patients with metastatic TNBC treated with sacituzumab govitecan maintained an efficacy benefit compared with physician's choice chemotherapy.

Neoadjuvant Durvalumab Plus Chemotherapy Effective in Early-Stage TNBC
June 06, 2021

Phase 2 results presented during the 2021 ASCO Annual Meeting suggest durvalumab plus chemotherapy as neoadjuvant therapy for triple-negative breast cancer may be beneficial in certain patients.

Outcome Data for Black Women With Early TNBC Suggest Research Needed to Combat Disparities
May 23, 2021

Black women with triple-negative breast cancer may have worse survival outcomes compared with White women, even after adjusting for external factors.